ASLAN Pharmaceuticals’ (ASLN) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN) in a research report report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $9.00 price target on the stock.

Separately, Piper Sandler reaffirmed an overweight rating and issued a $10.00 price target (down previously from $15.00) on shares of ASLAN Pharmaceuticals in a research note on Wednesday, March 13th.

ASLAN Pharmaceuticals Stock Performance

ASLN opened at $0.45 on Tuesday. ASLAN Pharmaceuticals has a fifty-two week low of $0.39 and a fifty-two week high of $4.69. The company has a market capitalization of $7.32 million, a P/E ratio of -0.16 and a beta of 1.45. The stock has a fifty day moving average of $0.60 and a 200-day moving average of $0.72.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last posted its quarterly earnings results on Friday, April 12th. The company reported ($0.78) EPS for the quarter. On average, equities research analysts predict that ASLAN Pharmaceuticals will post -2.68 earnings per share for the current fiscal year.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.